Neuron23 advanced its clinical programs with a $96.5 million Series D funding round reflecting investor confidence in neurology therapeutics. Separately, Adaptive Biotechnologies experienced a stock surge following updates to multiple myeloma treatment guidelines recommending baseline clonotype identification and aspirate sample storage to facilitate minimal residual disease testing, enhancing personalized oncology care.